Protecting Life from Chemical Abortions Act

Bill Number

H.R. 1525

Origin Chamber

House

Congress

119th Congress, Session 1

Policy Area

Health

Status

Introduced

Latest Action

2025-02-24: Referred to the House Committee on Energy and Commerce.

Last Updated

2026-06-11T08:07:02Z

AI-Generated Summary

Purpose of the Legislation

This bill, titled the "Protecting Life from Chemical Abortions Act," aims to restrict federal actions related to abortion, specifically by preventing the use of public health emergency declarations for abortion-related issues and imposing stricter regulations on abortion drugs (medications used to end pregnancies). It seeks to limit access to these drugs and require detailed reporting of abortion data from states.

Key Provisions

• Prohibition on Public Health Emergencies (Section 2): The Secretary of Health and Human Services (HHS) is barred from declaring or using a public health emergency under sections 319 or 319F-3 of the Public Health Service Act specifically for abortion. Any such existing declaration is immediately terminated upon enactment.

• Limitations on Abortion Drugs (Section 3):
• HHS officials, including the Food and Drug Administration (FDA) Commissioner, cannot use "enforcement discretion" (i.e., leniency in applying rules) for the Risk Evaluation and Mitigation Strategy (REMS)—a FDA safety plan for high-risk drugs—related to abortion drugs.
• The bill reinstates the "in-person dispensing requirement," mandating that abortion drugs be provided only in clinics, medical offices, or hospitals by or under the supervision of a "certified health care provider" (a qualified professional who has signed an agreement confirming their ability to assess pregnancies, diagnose complications, and provide or arrange emergency care).
• No reductions to REMS protections (e.g., via updates) or waivers of the in-person requirement are allowed until every state submits aggregate (non-individual) abortion data to the Centers for Disease Control and Prevention (CDC) surveillance system. This data must use a standardized format covering specific variables (detailed below).
• Mandatory Data Variables (for State Reporting): States must report aggregated data including:
• Maternal age (in years).
• Gestational age (weeks of pregnancy at abortion).
• Maternal race and ethnicity (including combined race-ethnicity).
• Abortion method type.
• Maternal marital status.
• Previous pregnancies (live births, induced abortions, spontaneous abortions/miscarriages).
• Maternal residence (state or county).
• Whether the child survived the abortion.
• Congenital anomalies (birth defects).

These variables become mandatory for Medicaid funding under section 1903(bb) of the Social Security Act.

• Definitions:
• Abortion: Use of any instrument, drug, or device to intentionally end a known pregnancy, excluding exceptions like medically indicated premature live births after viability (when the fetus can survive outside the womb), treatment of ectopic pregnancies (where the embryo implants outside the uterus), or removal of a dead fetus.
• Abortion Drug: Any medication or substance used for an abortion.
• Unborn Child: A human organism from fertilization until live birth.
• Certified Health Care Provider: A provider who agrees to REMS guidelines, including skills for pregnancy assessment, ectopic diagnosis, surgical intervention for complications, and access to emergency facilities.

Significant Changes to Existing Law

• Public Health Emergencies: Introduces a new outright ban on using emergency powers (under the Public Health Service Act) for abortion, reversing any prior or potential declarations that could expand access during crises (e.g., no emergency shipping or relaxed rules for abortion drugs).
• Abortion Drug Regulations: Reverses FDA's 2021 and 2023 decisions to ease REMS for drugs like mifepristone by mandating in-person dispensing and prohibiting waivers or leniency without full state data compliance. It ties FDA flexibility to a new national data-reporting mandate, expanding CDC surveillance requirements beyond current voluntary state reporting.
• Data Reporting: Elevates specific abortion data variables to mandatory status for federal Medicaid funding, potentially increasing state obligations compared to existing, less uniform reporting under the CDC.

Potential Impacts

• Government Agencies: HHS and FDA face enforced stricter oversight of abortion drugs, limiting their ability to adapt regulations without complete state data submission. The CDC must integrate and manage expanded aggregate data, potentially straining resources. States could incur costs for data collection and reporting to maintain Medicaid eligibility.
• Citizens: Pregnant individuals seeking medication abortions (e.g., via pills like mifepristone) may face reduced access, requiring in-person clinic visits and certified providers, which could increase barriers in rural or underserved areas. This might delay or prevent abortions, affecting reproductive health choices.
• International Relations: No direct impacts mentioned; the bill focuses on domestic U.S. health policy.

Main Stakeholders Affected

• Pregnant Individuals and Abortion Seekers: Directly limited in accessing abortion drugs without in-person requirements.
• Health Care Providers: Must comply with certification and dispensing rules; non-certified providers (e.g., via telehealth) are restricted.
• States and Public Health Agencies: Required to submit detailed aggregate data or risk losing federal Medicaid funds; affects data privacy and administrative burdens.
• Pharmaceutical Companies: Producers of abortion drugs (e.g., mifepristone manufacturers) face reinstated restrictions on distribution, potentially impacting sales and operations.
• Anti-Abortion Advocates and Policymakers: Sponsors (primarily Republican representatives) benefit from aligned restrictions; pro-choice groups may oppose as limiting access.

Notable Legal, Constitutional, or Political Implications

• Legal: Could face challenges under the Administrative Procedure Act for overriding FDA's drug approval authority or under federal preemption if conflicting with state abortion laws post-Dobbs v. Jackson Women's Health Organization (2022 Supreme Court decision returning abortion regulation to states). The broad abortion definition may invite litigation over exceptions like ectopic pregnancies.
• Constitutional: Raises potential issues with the right to privacy or due process (under the 14th Amendment) by restricting medical access, though it avoids direct bans on abortion itself. Ties to Medicaid could implicate equal protection concerns for low-income individuals.
• Political: Reflects a partisan push (introduced by conservative lawmakers) to federalize restrictions on medication abortion amid ongoing post-Roe v. Wade (1973, overturned) debates, potentially influencing national reproductive policy without addressing surgical abortions. Enactment would depend on congressional majorities and could spark broader debates on federal vs. state roles in health emergencies.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Rep. Hern, Kevin [R-OK-1]

Cosponsors (25)

Rep. Aderholt, Robert B. [R-AL-4], Rep. Feenstra, Randy [R-IA-4], Rep. Moolenaar, John R. [R-MI-2], Rep. Baird, James R. [R-IN-4], Rep. Weber, Randy K. Sr. [R-TX-14], Rep. Webster, Daniel [R-FL-11], Rep. Crenshaw, Dan [R-TX-2], Rep. Newhouse, Dan [R-WA-4], Rep. Green, Mark E. [R-TN-7], Rep. Boebert, Lauren [R-CO-4], Rep. Rutherford, John H. [R-FL-5], Rep. Bost, Mike [R-IL-12], Rep. Guest, Michael [R-MS-3], Rep. Self, Keith [R-TX-3], Rep. Downing, Troy [R-MT-2], Rep. Miller, Mary E. [R-IL-15], Rep. Davidson, Warren [R-OH-8], Rep. Rose, John W. [R-TN-6], Rep. Harrigan, Pat [R-NC-10], Rep. LaMalfa, Doug [R-CA-1], Rep. Hinson, Ashley [R-IA-2], Rep. Cline, Ben [R-VA-6], Rep. Biggs, Andy [R-AZ-5], Rep. Letlow, Julia [R-LA-5], Rep. Burlison, Eric [R-MO-7]

Recent Actions

• 2025-02-24: Referred to the House Committee on Energy and Commerce.
• 2025-02-24: Introduced in House
• 2025-02-24: Introduced in House

Bill Versions

• Protecting Life from Chemical Abortions Act — issued 2025-02-24 — PDF (6 pages)